Item 7.01 Regulation FD Disclosure.

On January 25, 2023, Pulmatrix, Inc. (the "Company") issued a press release, attached hereto as Exhibit 99.1, announcing that it will host a virtual key opinion leader (KOL) event, "PUR3100 for the Treatment of Acute Migraine: Unlocking Potential of DHE Treatment".

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing. Furthermore, the furnishing of information under Item 7.01 of this Current Report on Form 8-K is not intended to constitute a determination by the Company that the information contained herein, including the exhibits hereto, is material or that the dissemination of such information is required by Regulation FD.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits



Exhibit Number   Description

99.1               Press Release, dated January 25, 2023 (furnished herewith
                 pursuant to Item 7.01)
104              Cover Page Interactive Data File (formatted as Inline XBRL)

© Edgar Online, source Glimpses